Aspira Women’s Health announces $5.5M registered direct offering

Aspira Women’s Health has entered into definitive agreements with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company for the purchase and sale of 1,571,000 shares of its common stock in a registered direct offering and warrants to purchase up to an aggregate of 1,571,000 shares of common stock in a concurrent private placement at a combined purchase price of $3.50 per share to the institutional investor and certain existing investors and a purchase price per share of $4.255 per share to the officer of the Company. The warrants to the institutional investor and certain existing investors will have an exercise price of $4.00 per share and the warrants to the officer of the Company will have an exercise price of $4.13 per share, both warrants to the existing shareholders and the officer of the Company will be exercisable beginning six months after issuance and will expire 5 years from the initial exercise date. All of the securities in the Offering are being sold by Aspira. The closing of the Offering is expected to occur on or about January 26, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $5.5 million. The Company intends to use the net proceeds from the Offering for general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering.